Currently out of the existing stock ratings of Debanjana Chatterjee, 30 are a BUY (93.75%), 2 are a HOLD (6.25%).

Debanjana Chatterjee

Work Performance Price Targets & Ratings Chart

Analyst Debanjana Chatterjee, currently employed at JONESTRADING, carries an average stock price target met ratio of 25.45% that have a potential upside of 36.5% achieved within 43 days.

Debanjana Chatterjee’s has documented 62 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CTNM, Contineum Therapeutics at 15-Oct-2026.

Wall Street Analyst Debanjana Chatterjee

Analyst best performing recommendations are on ABCL (ABCELLERA BIOLOGICS).
The best stock recommendation documented was for ABSI (ABSCI CORP) at 5/12/2026. The price target of $11 was fulfilled within 48 days with a profit of $5.64 (105.22%) receiving and performance score of 21.92.

Average potential price target upside

ABSI Absci Corp KALV Kalvista Pharmaceuticals NTLA Intellia Therapeutics SGMT Sagimet Biosciences TBPH Theravance Biopharma ABCL Abcellera Biologics CTNM Contineum Therapeutics SYRE Spyre Therapeutics TRVI Trevi Therapeutics PHVS Pharvaris BV

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 05-Dec-2023

$20

$9.83 (96.66%)

$9

27 days ago
(16-Oct-2026)

6/7 (85.71%)

$11.75 (142.42%)

236

Buy Since 16-May-2023

$16

$5.83 (57.33%)

$16

1 months ago
(12-Oct-2026)

12/14 (85.71%)

$5.84 (57.48%)

453

Buy Since 22-Jan-2025

$11

$0.83 (8.16%)

$11

1 months 20 days ago
(23-Sep-2026)

13/13 (100%)

$1.25 (12.82%)

216

Buy Since 28-May-2026

$16

$5.83 (57.33%)

$13

2 months 4 days ago
(08-Sep-2026)

1/4 (25%)

$7.09 (79.57%)

27

Buy Since 08-May-2026

$17

$6.83 (67.16%)

$11

4 months 10 days ago
(02-Jul-2026)

1/2 (50%)

$5.38 (46.30%)

52

Show more analysts

Please expand the browser size to see the chart

Which stock is Debanjana Chatterjee most bullish on?

Potential upside of $20.48 has been obtained for CTNM (CONTINEUM THERAPEUTICS)

Which stock is Debanjana Chatterjee most reserved on?

Potential downside of -$0 has been obtained for TBPH (THERAVANCE BIOPHARMA)

What Year was the first public recommendation made by Debanjana Chatterjee?

On 2024
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?